Vaxart's (VXRT) Oral Vaccine points to strong mucosal protection in NHP, now in Phase 2 Clinical Trial.

 

Stock Talk

Vaxart, Inc.

Newly published data demonstrates substantial cross-reactivity against multiple variants of COVID-19

S-only candidate is believed to be the first to demonstrate robust neutralizing antibody responses in mucosal sites, which is where primary infection occurs

Vaxart’s S-only candidate induced a 1000-fold increase in nasal IgA responses to the variants, which could have substantial impact on reducing community transmission

https://finance.yahoo.com/news/vaxart-only-covid-19-vaccine-133000574.html

_______

ALL in my humble opinion, scroll down and read more.

This site does NOT make Buy / Sell recommendations.
_______